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Breast cancer is the leading cause of cancer deaths among women. Results
from experimental studies suggest that tumour progression and metastasis in
breast cancer are angiogenesis dependant. The College of American Patholo-
gists has stated that further study of quantification of tumour angiogenesis is
still required to demonstrate its prognostic value in breast cancer.
In this study, not only the microvascular density (MVD), but also the vascular area
ratio (VAR), and the vascular count in different grades of invasive ductal breast
carcinoma were assessed using a pan-endothelial marker, CD34, and monoclonal
antibody to CD105, by employing computer assisted morphometric measurements.
In addition, quantitative expression of vascular endothelial growth factor (VEGF)
was detected. Correlation of the vascular parameters and VEGF expression with
the different grades of invasive ductal breast carcinoma was clarified.
Immunohistochemical staining for the CD105, CD34, and VEGF antibodies were
performed in 25 patients with invasive ductal carcinoma in King Fahd Hospital,
Saudi Arabia. Normal breast tissue samples comprised 15 specimens detected
at the safety margin of the malignant breast cases were collected.
Positive CD34 stained blood-vessel endothelial cells were observed in all nor-
mal breast tissues. In contrast, CD105 and VEGF expression were not expressed
in the normal breast ducts and lobules. Widespread staining for CD34, to
a lesser extent CD105, and VEGF expression were seen in all tumour specimens
with different grades. Significant differences in the vascular parameters, stained
with antiCD34, were observed between normal breast tissues and invasive ductal
carcinoma. In addition, the vascular parameters stained with antiCD34 and
antiCD105, and the percentage of VEGF expression in the three grades of inva-
sive ductal carcinomas showed significant differences with positive correlations.
In conclusion, MVD as well as VAR are considered to reflect the final result of
the tumour angiogenesis cascade. In addition, VEGF expression was found to
be a useful angiogenic marker. However, few cases were VEGF negatively
stained. Thus, the expression of MVD, VAR, and to a lesser extent VEGF might
be reference predictors for the biological behaviour and prognosis of breast
carcinoma. (Folia Morphol 2009; 68, 3: 144–155)
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INTRODUCTION
Angiogenesis is the term coined by Folkman in
1971 [17] to identify the complex process leading to
the formation of new blood vessels from the pre-
existing vascular network. The growth, invasion, and
metastasis of many cancers depend on angiogene-
sis; solid tumours require neovascularization to grow
beyond about 1 mm3. Angiogenesis in the tumour
can be evidenced by immunohistochemical labelling
techniques [9]. Immunohistochemical analysis has the
advantages of being readily available in the clinical
setting and of enabling morphological evaluation of
expression patterns.  Finding the different markers
associated with angiogenesis may help to identify
patients at increased risk for recurrence and metasta-
sis, and thus those who require more aggressive the-
rapy and closer surveillance [39]. In addition, the
quantification of tumour microvasculature is a can-
didate target for antiangiogenic therapy [10].
To date, however, no such marker has been definit-
ively identified. Discrepancies between different stud-
ies may be due to the various methods of staining
tissues using different endothelial marker antibodies
and different methods of counting microvessels. Since
these studies have been done in series of patients hav-
ing different pathological and clinical characteristics,
a proper meta-analysis is not possible.
One method for detection of the degree of
neovascularization is the microvascular density
(MVD). Several researchers have demonstrated that
the MVD is closely correlated with the prognosis of
breast cancer [33]. The assessment of microvessel
density was developed by Weidner et al. [37], ini-
tially using antibodies against factor VIII-related
antigen that stain mainly mature vessels. The more
recent use of antibodies against CD34 react not only
with newly formed vessels but also normal vessels
trapped within tumour tissues and are thus referred
to as pan endothelial markers [39].
The association of CD105 with angiogenesis ini-
tially came from Wang et al. [36] who found that
monoclonal antibodies to CD105 reacted strongly
with the endothelium in various tumour tissues but
only weakly in normal tissues [40]. Endoglin (CD105),
a cell membrane glycoprotein predominantly ex-
pressed on cellular lineages within the vascular sys-
tem, and over-expressed on proliferating endothe-
lial cells, is involved in blood vessel development and
represents a powerful marker of neovascularization.
CD105 binds several factors of the transforming
growth factor beta (TGF-b) superfamily, a pleiotro-
pic cytokine that regulates different cellular func-
tions including proliferation, differentiation, and mi-
gration [29].
Other methods have been developed to assess
the expression or concentrations of certain angio-
genic factors. Among these angiogenic factors,
vascular endothelial growth factor (VEGF) has been
found to be the most essential factor for differen-
tiation and development of the vascular system.
Much evidence indicates that VEGF is a key acti-
vator of angiogenesis [16]. It is a highly specific
and selective mitogen for vascular endothelial
cells. In vivo, VEGF is necessary for vasculogene-
sis, promotes angiogenesis, and enhances vascu-
lar permeability in breast cancer [22]. Evidence for
the pivotal role of this cytokine in tumour angio-
genesis includes the observations of increased ex-
pression in tumour cells of numerous human can-
cers together with up-regulation of the receptors
on the associated endothelial cells and the inhi-
bitory effect of antiVEGF antibodies on tumour
growth in vivo. Disruption of the capacity to pro-
duce or up regulate these factors should help to
control the progression of cancer [1].
Semi-quantitative evaluation of immunohis-
tochemical labelling is easy to perform and cost-ef-
fective, but computerized systems of image analy-
sis, developed to quantify positive immunoprecipi-
tates within tissue sections, are more reproducible
and therefore more acceptable for clinical and patho-
logical use [11].
Malignant changes of the breast constitute as
many as one in ten women, and the incidence con-
tinues to rise. Breast cancer is the leading cause of
cancer deaths among women aged 20 to 59 years
[27]. Results from experimental studies suggest that
tumour progression and metastasis in breast can-
cer are angiogenesis dependant [22]. The College
of American Pathologists has stated that further
study of quantification of tumour angiogenesis is
still required to demonstrate its prognostic value in
breast cancer [17].
In this study, not only the MVD, but also the vas-
cular area ratio (VAR), and the vascular count (VC)
in different grades of invasive ductal breast carcino-
ma were assessed using a pan-endothelial marker,
CD34, and a more specific monoclonal antibody to
CD105, by employing computer assisted morpho-
metric measurements. In addition, quantitative ex-
pression of VEGF was detected.  Correlation of the
vascular parameters and VEGF expression with the
different grades of invasive ductal breast carcino-
ma was clarified.
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MATERIAL AND METHODS
Patients and specimens
This study included 25 patients ranging in age
from 30 to 60 years old (mean ± SEM = 49.52 ±
± 1.65 years) with invasive ductal carcinoma who
underwent modified radical mastectomy surgery in
King Fahd Hospital, Saudi Arabia. The patients did
not receive chemotherapy or hormone therapy be-
fore surgery. Appropriate local ethical committee
approval was obtained. Normal breast tissue sam-
ples comprised 15 specimens detected at the safety
margin of the malignant breast cases. Clinical fea-
tures evaluated in malignant cases were age and
menopausal status. The malignant breast specimens
were divided according to menopausal status into
12 pre-menopausal patients (£ 50 years) and 13 post-
menopausal patients (> 50 years) [31].
All tumour samples had been fixed in 10% buff-
ered formalin and then embedded in paraffin. Serial
5-mm sections obtained from each specimen were sub-
jected to routine haematoxylin and eosin staining for
pathological diagnosis. Tumours were graded accord-
ing to a modified version of Scarff-Bloom-Richardson
system (based on tubule formation, nuclear grade, and
mitotic count) [15]. Grade I, II, and III of invasive duc-
tal carcinomas were detected in 5 cases (20%), 14 cas-
es (56%), and 6 cases (24%), respectively.
Immunohistochemistry
Immunostaining was performed on formalin-fixed,
paraffin-embedded tissue sections following the stan-
dard streptavidin-biotin-peroxidase 3,3'-diaminobenzi-
dine immunohistochemical technique according to the
immunohistochemical staining protocol [34]. Briefly,
deparaffinised and rehydrated tissue sections were in-
cubated in 3% hydrogen peroxide diluted with metha-
nol for 30 minutes to block the endogenous peroxi-
dase activity. Antigen retrieval was performed by first
pretreating sections in a microwave oven or incubating
them in 0.1% trypsin for 10 minutes at 37.0°C, after
which nonspecific immunoreactivity was blocked by
incubating the tissue in normal goat serum at room
temperature for 5 minutes before application of the
monoclonal antibody to CD105, CD34, or VEGF (Lab
Vision Corporation, USA), which were diluted with phos-
phate-buffered saline at a ratio of 1:100. The sections
were then washed in PBS and sequentially incubated in
biotinylated goat anti-mouse immunoglobulin G and
a streptavidin-biotinylated horseradish-peroxidase com-
plex, according to the manufacturer’s instructions (Lab
Vision Corporation, USA). The staining was performed
by immersing slides in 0.05% 3,3’-diaminobenzidine
tetrahydrochloride. All tissue sections were counter-
stained with haematoxylin, dehydrated, and mounted.
The assessment of immunostaining was made by two
independent investigators using light microscope. Pos-
itive control slides were included in all cases.
Evaluation of vascularization
The area of most intense microvascularisation
was selected by scanning on low magnification
(× 40) to identify three areas with the highest den-
sity of microvessels (“hotspots”). Each hotspot was
then evaluated at high power magnification (× 200)
for the number of stained microvessels per field. Any
brown-staining endothelial cell containing a visible
nucleus, and clearly separate from adjacent mi-
crovessels, tumour cells, and other connective-tis-
sue elements, was considered a single, countable
microvessel, without requirement for a lumen or the
presence of erythrocytes [7]. Larger vessels with mus-
cular walls were excluded from counting. The mean
of three fields were chosen from each slide, to best
reflect the overall immunostaining of the vessels.
Counting was performed by two independent ob-
servers.
Immunoreactivity for VEGF was detected in the
tumour cells. A tumour area with any degree of stain-
ing was scored as VEGF-positive. Tumours with VEGF-
-positive and VEGF-negative areas were assigned the
score of the area with strongest staining [1].
Computer-assisted morphometric analysis
Computer-assisted analysis was performed as
previously described [4]. Digitized pictures were vi-
sualized on a high-resolution colour display. Mea-
surements and data collection were carried out us-
ing digital image processing and analysis software
for professional microscopy (Leica QWin microsys-
tem, United Kingdom). The collected measurements
were presented as mean ± standard error of mean.
In normal specimens, two parameters were cho-
sen for microvascularisation description: MVD: [mi-
crovessel number/(microvessel area + residual stro-
mal area)] × 10000; and VAR: [microvessel area/(mi-
crovessel area + residual stromal area)]; in both lo-
bules and ducts. The residual stromal area (RSA) was
calculated by subtracting the ductal and the vascu-
lar areas from the total ductal area in breast ducts
(Fig. 1A, B), or by subtracting the acinar and the
vascular areas from the total lobular area in breast
lobules (Fig. 2A–C) [25]. The ductal area was mea-
sured as the overall area occupied by the duct, in-
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Figure 1. A. Normal breast duct stained with antiCD34 showing microvessels in periductal stroma (¥ 200); B. Computer image
processing of the same duct illustrated in Figure 1A, showing the microvessels (black markings) (¥ 200).
Figure 2. A. Normal breast lobule immunostained with antiCD34 (¥ 200); B. Computer image processing of the same lobule illustrated
in Figure 2A, showing the microvessels (black markings) (¥ 200); C. Computer image processing of the same lobule illustrated in
Figure 2A, showing the acini (black markings) (¥ 200); D. Computer image processing of the same lobule illustrated in Figure 2A,
showing the total breast lobule area (black markings) (¥ 200).
cluding the lumen, epithelial wall, and a 200-µm rime
of stroma around the duct. In invasive ductal carci-
nomas, the microvascular density was calculated as
the (number of vessels/assessed field area) ¥ 10000
and the vascular area ratio as the vessel area/as-
sessed field area [13, 28].
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The percentage of cancer cells having cytoplas-
mic staining for VEGF was recorded. Staining was
graded in a four-grade classification as follows:
–, for those where reactivity was not detected;
1+, those with positive stain in less than 5% of
tumour cells; 2+, a positive stain between 5%
and 50%; and 3+, when greater than 50% posi-
tive [41].
Staining results were analyzed against histologi-
cal differentiation. The association between the vas-
cular parameters and various pathological grades
were analyzed statistically by one-way analysis of
variance (ANOVA) followed by Tukey’s HSD (honest-
ly significant difference) pair wise comparisons. The
level of significance was set at p < 0.05 throughout
the study. The correlations between the calculated
parameters regarding the microvasculature with
CD34 and CD105, and VEGF expressions, were mea-
sured by Pearson’s correlation coefficient. The cur-
rent SPSS (version 13) statistical package was used
in all statistical analysis [9].
RESULTS
CD34 and CD105 expression
Positive CD34 stained blood-vessel endothelial
cells were observed in all normal breast tissues
(Fig. 1, 2). Widespread staining for CD34 was also
seen in all tumour specimens with different grades
as shown in the figures (Fig. 3A–C).
In contrast, CD105 was not expressed in the vas-
cular endothelial cells of the normal breast tissues
(Fig. 4, 5), but was expressed in the vascular endo-
thelial cells of invasive ductal carcinoma with differ-
ent grades (Fig. 6A–C). CD105 expression was mostly
observed in the peripheral non- necrotic tumour tis-
sues. It was also observed that the staining of en-
dothelial cells with antiCD34 was intense and easy
to visualize, more so than those stained with anti-
CD105 antibody.
VEGF expression
VEGF expression was not detected in normal
mammary tissues (Fig. 7, 8). Positive staining of tu-
mour cells for VEGF was observed in different grades
of invasive ductal carcinomas (Fig. 9A–C). Positive
VEGF expression was found in 92% of breast carci-
nomas. The staining was heterogeneous in most of
the tumours evaluated, comprising areas of intense
and weak staining. A characteristic granular cyto-
plasmic staining pattern, independent of vessel proxi-
mity, was demonstrated. In some areas, membra-
Figure 3. Immunostained grade I (A), grade II (B), and grade III (C)
invasive ductal carcinoma of the breast with antiCD34. Note the
increased number of microvessels with increased grade (¥ 200).
nous and cytoplasmic positive staining were ob-
served (Fig. 9B). A weak and focal positive reaction
of intervening stromal cells (fibroblasts and/or mac-
rophage) was also seen in some cases. Labelling of
intratumoural macrophages is shown in Figure 10.
Expression of VEGF was found to be negative in 8%,
weak in 0%, moderate in 12%, and strong in 80%
of breast carcinomas.
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Statistical analysis
The vascular parameters (MVD, VAR, and VC) of
normal breast ducts and lobules stained with antiCD34
was measured as shown in Table 1.
Significant differences in the microvascular den-
sity, vascular area ratio, and vascular count, stained
with antiCD34, were observed between normal
breast tissues (lobules and ducts) and invasive duc-
tal carcinoma of the breast (Table 2).
The vascular parameters stained with antiCD34
and antiCD105, and the percentage of VEGF expres-
sion in the three grades of invasive ductal carcinomas
showed significant differences, being highest in grade III
(Table 3). The VAR of antiCD34 and antiCD105, and
VEGF expression showed higher statistical significance
than the other parameters. No significant differences
were detected in these vascular parameters between
premenopausal and postmenopausal cancer patients
(Table 4).
A positive correlation was observed between the
vascular parameters of CD34- and CD105-stained
endothelial cells. Figure 11 shows a positive correlation
between CD34-MVD and CD105-MVD (r2 = 0.049).
In addition, a positive correlation was detected between
Figure 6. Immunostained grade I (A), grade II (B), and grade III (C)
invasive ductal carcinoma of the breast with antiCD105. Note the
presence of microvessels near the periphery of tumour tissue in
Figure 6C (¥ 200).
Figure 4. Negative immunostained normal breast lobule with
antiCD105 (¥ 200).
Figure 5. Negative immunostained normal breast duct with
antiCD105 (¥ 200).
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the VEGF expression and the vascular parameters of
CD34 and CD105 antibodies. Figure 12 shows the
correlation between VEGF expression and CD105-MVD
(r2 = 0.176). However, no correlation was found
between these vascular parameters or VEGF expres-
sions and the age of cancer patients.
DISCUSSION
Angiogenesis is crucial for tumour development
and progression, and antiangiogenetic therapy rep-
resents a promising approach for cancer treatment
[19, 20]. The original concept of antiangiogenic ther-
apy as an alternative adjuvant to traditional anti-can-
cer therapies has attracted enormous attention for
the past three decades. Equally important to antian-
giogenic therapy is the search for markers that can
be used for monitoring the efficacy of antiangiogen-
ic therapy and predicting tumour progression [6].
In the present study, the mean of microvascular
density of normal breast ducts and lobules stained with
antiCD34 antibody was 1.05 ± 0.21 and 1.09 ± 0.12,
respectively. However, Naccarato et al. [25] found it
to be 2.95 ± 0.16 in ducts and 2.48 ± 0.14 in lobules,
using antibody against CD34. Additionally, the mean
of the vascular area ratio in the present study was
Figure 7. Negative immunostained normal breast duct with
antiVEGF (¥ 400).
Figure 8. Negative immunostained normal breast lobule with
antiVEGF (¥ 400).
Figure 9. Immunostained grade I (A), grade II (B), and grade III (C)
invasive ductal carcinoma of the breast with antiVEGF. Note
the membranous and cytoplasmic positive staining in Figure 9B
(¥ 400).
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0.04 ± 0.01 in ducts and 0.05 ± 0.01 in lobules. These
findings are in-contrast to those of Naccarato et al.
[25], who reported that the mean vascular area ratio
was 0.29 ± 0.03 in ducts and 0.33 ± 0.02 in lobules.
The vascular parameters measured (MVD, VAR,
VC) in this study, using antibodies directed against
CD34, were significantly enhanced in malignant
lesions as compared to normal breast specimens.
The same finding was reported by Teo et al. [32],
who found that pure ductal carcinoma in situ ex-
hibited a greater density of CD34+ and CD31+ ves-
sels, compared to normal lobules. The microves-
sel density was significantly increased in the
present study in high-grade carcinomas compared
to low grades. In addition, some authors [35] have
reported that the mean vascular density increased
with lesion severity.
In the present work, the mean microvessel den-
sity was 84.12 ± 5.49, and the vascular area ratio
was 9.18 ± 1.29 in cases of invasive ductal carcino-
mas stained with antiCD34 antibody. Dromain et
al. [13] reported that the median values of the CD34+
intratumoural microvessel density and the intratu-
moural microvessel surface area in breast carcino-
mas were 79.2 and 2.6 microvessels per square mil-
limetre, respectively.
Figure 10. Labelling of intratumoural macrophages with antiVEGF
(¥ 400).
Table 1. Morphometric vascular parameters* of normal
breast tissues (ducts and lobules) using CD34 antibody
Vascular Normal ducts Normal lobules
parameters (n = 15) (n = 15)
VC 12.07 ± 2.06 14.67 ± 1.95
MVD 1.05 ± 0.21 1.09 ± 0.12
VAR 0.04 ± 0.01 0.05 ± 0.01
*Values are presented as means ±SEM; VC — vascular count,
MVD — microvascular density, VAR — vascular area ratio
Table 3. Vascular parameters* of the three grades of invasive ductal breast carcinomas using CD34, CD105, and
vascular endothelial growth factor (VEGF) antibodies
Angiogenic markers Grade I (n = 5) Grade II (n = 14) Grade III (n = 6) Significance
VC (CD34) 21.00 ± 2.85 33.14 ± 2.81 35.83 ± 2.68 0.03
MVD (CD34) 56.33 ± 7.63 88.90 ± 7.53 96.12 ± 7.18 0.03
VAR (CD34) 4.29 ± 1.03 8.40 ± 0.54 15.07 ± 4.43 0.01
VC (CD105) 4.20 ± 1.24 7.00 ± 0.87 9.83 ± 1.54 0.03
MVD (CD105) 11.27 ± 3.33 18.78 ± 2.34 26.38 ± 4.12 0.03
VAR (CD105) 3.44 ± 1.82 8.76 ± 1.37 19.13 ± 2.34 0.00
VEGF 22.40 ± 9.82 78.56 ± 3.48 85.85 ± 5.19 0.00
*Values are presented as means ±SEM; VC — vascular count, MVD — microvascular density, VAR — vascular area ratio
Table 2. Vascular parameters* of normal breast tissues and malignant breast lesions using CD34 antibody
Vascular Normal specimens Malignant breast Significance
parameters (n = 15) lesions (n = 25)
Vascular count 13.37 ± 1.41 31.36 ± 2.05 0.00
Microvascular density 1.07 ± 0.12 84.12 ± 5.49 0.00
Vascular area ratio 0.05 ± 0.01 9.18 ± 1.29 0.00
*Values are presented as means ±SEM
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In this study, statistical analysis of the 25 can-
cer patients showed that CD105 expression was in-
creased in higher grade carcinomas. This finding
was in accordance with Gabriel et al. [21] who
found that MVD-CD105 was greater in grade III
than in grade II, indicating an increase in the vas-
cular neoformation, something which must be eva-
luated as a possible prognostic factor in breast car-
cinomas. Also, Zhou et al. [41] observed that in-
creasing MVD was linked with increasing tumour
grade and stage.
In the present findings, the mean value of MVD
of CD105 expression on endothelial cells of invasive
ductal carcinomas was 10 ± 3.92 in grade I, and
18.78 ± 2.34 in grade II, in comparison to 26.38 ±
± 4.12 in grade III, with a total mean of 19.10 ±
± 1.98. Zhou et al. [41] reported the mean of MVD
to be 10.63 ± 7.54 in grade I, 14.98 ± 5.72 in grade II,
and 18.36 ± 6.01 in grade III, with a total mean
value of MVD of 15.22 ± 6.93. Beresford et al. [3]
mentioned that the median CD105-positive vessel
counts per field ranged from 0 to 18.5 (median 4),
a finding that was lower than that detected in this
study (median 7). In this research, the CD105 im-
munoexpression in cancer specimens was mainly at
the periphery of the tumour. However, Fonsatti et
al. [19, 20] mentioned that Endoglin is mainly
present on endothelial cells of both peri- and intra-
tumoural blood vessels, while it is weakly expressed
or absent on neoplastic cells.
The present work also showed that CD34 expres-
sion was universally expressed within normal and
malignant tissues, whereas CD105 expression was
absent in normal tissues but positively expressed in
breast carcinoma. These data suggest that both
CD105 and CD34 could be used for quantification
of angiogenesis, but preference should be given to
CD105 in the evaluation of prognosis in breast car-
Table 4. Vascular parameters* of premenopausal and postmenopausal women with invasive ductal breast carcinomas
using CD34, CD105, and vascular endothelial growth factor (VEGF) antibodies
Angiogenic markers Premenopausal (n = 12) Postmenopausal (n = 13) Significance
VC (CD34) 34.17 ± 3.55 28.77 ± 2.07 0.19
MVD (CD34) 91.65 ± 9.52 77.17 ± 5.54 0.19
VAR (CD34)  9.91 ± 2.28 8.50 ± 1.39 0.60
VC (CD105) 8.33 ± 0.91 6.00 ± 1.09 0.12
MVD (CD105) 22.35 ± 2.43 16.09 ± 2.91 0.12
VAR (CD105) 11.51 ± 1.82 8.96 ± 2.30 0.40
VEGF 69.33 ± 7.86 68.84 ± 8.26 0.97
*Values are presented as means ±SEM; VC — vascular count, MVD — microvascular density, VAR — vascular area ratio
Figure 12. Correlation between VEGF expression and
CD105 MVD.
Figure 11. Correlation between CD34 MVD and CD105 MVD.
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cinoma. This was in accordance with the work of
Ding et al. [12], Dales et al. [11], and Beresford et
al. [3]. Unlike CD34, which stains both mature and
immature vessels, CD105 appears to be much more
specific for new, immature vessels. Moreover,
Charpin-Taranger et al. [10] and Fonsatti et al. [19,
20] mentioned that CD105 immunodetection may
also be considered as a potential tool for selecting
patients that could benefit from specific antiangio-
genic therapy, using antiCD105 conjugates. Thus,
CD-105 can be used as a potential target of therapy
in breast carcinoma. Destroying the tumour-associ-
ated microvasculature without severely damaging
normal tissues or causing major adverse effects is
an appropriate goal for biological therapy.
In the present study, immunohistochemical stain-
ing for endothelial-specific markers CD34 antigen,
or CD105 antigen were clearly highlighted in the
vascular endothelium, with a strong staining reac-
tion in the former. However, methodological prob-
lems such as inter- and intra-observer variability, the
heterogeneity of the tumour, and selection of the
area of most intense neovascularization (“hotspot”)
remain unsolved. Absolute vessel counts are also
influenced by total magnification, selection of the
examination area, and the skill and experience of
the investigator. Extensive efforts have been made
to assess angiogenesis objectively. Calculating the
vascular area by computer-assisted methods, e.g.,
image analysis, was reported to be useful in prog-
nosis [30]; however, another study failed to dem-
onstrate any prognostic significance [24]. In the
present study, VAR was significantly increased with
tumour grade by immunohistochemical staining
with antiCD34 and anti CD105, a finding which
should be taken into consideration. Charpin et al. [9]
mentioned that to provide more standardized data
for the quantification of immunocytochemical stud-
ies, diverse computerized image analysis systems
have been employed and were found to correlate
well with semi-quantitative histological scoring
methods and with biochemical data.
VEGF is over-expressed in several malignant tu-
mours as well as in healing wounds, in rheumatoid
arthritis, and in delayed hypersensitivity skin reactions.
It stimulates angiogenesis by increasing vascular per-
meability and by acting as an endothelial-cell mito-
gen [14]. In the present study, 92% of invasive duc-
tal carcinomas were found to be VEGF positive. This
was in agreement with Adams et al. [1] who men-
tioned that the VEGF positivity was 80%. Nieto et
al. [26] detected intratumoural VEGF expression in 51%
of patients, and Al-Harris et al. [2] observed VEGF
positivity in 61.5% of malignant breast lesions. How-
ever, Karavasilis et al. [23] found VEGF-positive ex-
pression in all cases of cancers of unknown primary,
and VEGF was overexpressed in the majority. The
pattern of VEGF immunohistochemical staining in the
present research was in accordance with Adams et
al. [1] and Karavasilis et al. [23]. Both membranous
and cytoplasmic staining was observed, a finding
which was also reported by Karavasilis et al. [23].
In the present work, VEGF was not detected in
normal breast ducts and lobules, a finding similar to
that reported by Zhou et al. [41]. Al-Harris et al. [2]
observed no over expression of VEGF in normal breast
tissues. In addition, occasionally normal epithelial cells
and stromal components showed faint staining for
VEGF, particularly adjacent stromal endothelial cells,
as was reported by Viacava et al. [35]. In normal or-
ganisms, angiogenesis is strictly controlled, but in
tumours, angiogenesis is uncontrolled and immature.
In the present work, expression of VEGF was
found to be negative in 8%, weak in 0%, moderate
in 12%, and strong in 80% of breast carcinomas.
Also, Zhou et al. [41] found the expression of VEGF
negative, weak, moderate, and strong in 29 (23.8%),
38 (31.1%), 34 (27.9%), and 21 (17.2%) of tumour
tissues, respectively.
The prognostic importance of VEGF in invasive
breast cancer is associated with tumour grade. It
was higher in grade III than in grade I. This is in
agreement with Callagy et al. [8] and Zhou et al.
[41]. In addition, Al-Harris et al. [2] reported that
vascular endothelial growth factor immunostaining
was positively correlated with tumour grade and
stage. Gasparini [22] stated that VEGF could be an
important marker of angiogenic activity for prog-
nostic purposes as well as for targeting inhibition of
angiogenesis as a novel therapeutic strategy against
cancer. However, Nieto et al. [26] did not find any
correlation between VEGF expression and histolo-
gical grade
In the present work, assessment of VEGF expres-
sion by immunohistochemistry in invasive ductal
carcinoma has shown significant correlation with
microvessel counts or density, indicating that both
are markers of the degree of angiogenesis, a find-
ing which was also reported by Adams et al. [1],
Karavasilis et al. [23], Bolat et al. [5], and Wei-guo
et al. [38]. However, other researches showed no
correlation between VEGF expression and the de-
gree and/or type of vascularization [26, 34]. Callagy
et al. [8] mentioned that tumour stage correlated
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with tumour VEGF, but not with microvessel “hot-
spot” or vessel counts, and routine measurement of
microvessel density in breast cancer is less reliable.
Their findings may reflect the relatively small sam-
ple size, the relatively uniform patient populations
examined in many earlier studies, antibody specifi-
city, or variability in the techniques used to assess
immunohistochemical staining or angiogenesis.
No correlation was found between intratumoural
VEGF expression and vascular parameters with pa-
tient’s age. Also, no significant differences in the
vascular parameters and VEGF were observed with
the menopausal status of cancer patients.  This was
in accordance with other studies [1].
In conclusion, MVD and VAR are considered to
reflect the result of the tumour angiogenesis cas-
cade. In this work, we found that angiogenesis is
very active in breast cancer, and is increasing with
cancer grade. Several researchers have evaluated the
MVD in invasive ductal carcinomas of the breast,
with very limited reports regarding the VAR of CD105
or CD34 expressions. In this research, it was found
that VAR gave the same prognostic value as that of
MVD in cancer breast. In addition, VEGF expression
was found to be a useful angiogenic marker. How-
ever, few cases were negatively stained. Due to the
heterogeneity of staining reaction, the counting of
positive cells may be subjected to personal variabil-
ity. Thus, the expression of MVD, VAR, and to a less-
er extent VEGF might be reference predictors for the
biological behaviour and prognosis of breast carci-
noma.
These conclusions may provide important theo-
retical evidence for cancer therapy through antian-
giogenesis. The results of this work also indicate the
possible value of using these biological markers to
predict the risk of micro-metastasis in breast can-
cer. Our results require confirmation in a greater
number of patients with a long follow up.
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